SCHEMBL24678051

SCHEMBL24678051

CC(C)(C)OC(=O)C(CCCCCCCCCCC(=O)OCc1ccccc1)(CCCCCCCCCCC(=O)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
MAPK1 P28482 2/20 0.42
EPHX2 P34913 1/20 0.41
LMNA P02545 1/20 0.40
SYK P43405 1/20 0.39
PTPN1 P18031 2/20 0.39
PTPRC P08575 1/20 0.39
MBOAT4 Q96T53 1/20 0.39
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37
FAAH O00519 1/20 0.36
MGLL Q99685 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24678110 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL24678178 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL24678074 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL20943360 0.97 ALDH1A1 (0.44) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL20943370 0.97 ALDH1A1 (0.44) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL22465770 0.96 ALDH1A1 (0.45) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL16412141 0.95 MBOAT4 (0.45) ALDH1A1L3MBTL1MAPK1PTPN1MBOAT4
SCHEMBL24678166 0.93 L3MBTL1 (0.49) ALDH1A1L3MBTL1MAPK1EPHX2LMNA
SCHEMBL20943365 0.93 MBOAT4 (0.46) ALDH1A1L3MBTL1MAPK1EPHX2PTPN1
SCHEMBL20943336 0.93 MBOAT4 (0.46) ALDH1A1L3MBTL1MAPK1EPHX2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240247042-A1 GLUCAGON LIKE PEPTIDE COMPOUNDS NOVARTIS AG (CH) 2024-07-25 US disclosed
EP-4326330-A1 GLUCAGON LIKE PEPTIDE COMPOUNDS Novartis AG (CH) 2024-02-28 EP disclosed
WO-2022224164-A1 GLUCAGON LIKE PEPTIDE COMPOUNDS NOVARTIS AG (CH) 2022-10-27 WO disclosed
WO-2022224164-A1 GLUCAGON LIKE PEPTIDE COMPOUNDS NOVARTIS AG (CH) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240247042-A1 GLUCAGON LIKE PEPTIDE COMPOUNDS GLP1R, IAPP, GPR119 ALDH1A1 3655/4885L3MBTL1 1885/4885MAPK1 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.